{"id":"placebo-matching-saxagliptin","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypoglycemia"},{"rate":null,"effect":"Upper respiratory tract infection"},{"rate":null,"effect":"Urinary tract infection"},{"rate":null,"effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL2103745","moleculeType":"Small molecule","molecularWeight":"333.43"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Saxagliptin inhibits dipeptidyl peptidase-4 (DPP-4), an enzyme that degrades glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). By blocking DPP-4, saxagliptin increases circulating levels of these incretin hormones, which enhance glucose-dependent insulin secretion and reduce glucagon secretion, thereby lowering blood glucose levels in type 2 diabetes. As a placebo matching formulation, this product contains no active saxagliptin and is used as a control in clinical trials.","oneSentence":"This is a placebo control formulation matching Saxagliptin, a DPP-4 inhibitor that increases incretin hormone levels to stimulate insulin secretion in response to glucose.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:51:30.842Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Placebo control for type 2 diabetes mellitus trials"}]},"trialDetails":[{"nctId":"NCT03199053","phase":"PHASE3","title":"Study to Evaluate Safety and Efficacy of Dapagliflozin and Saxagliptin in Patients With Type 2 Diabetes Mellitus (T2DM) Aged 10 to Below 18 Years Old","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2017-10-11","conditions":"Diabetes Mellitus, Type 2","enrollment":256},{"nctId":"NCT03660683","phase":"PHASE4","title":"Effect of Saxagliptin and Dapagliflozin on Endothelial Progenitor Cell in Patients With Type 2 Diabetes Mellitus","status":"TERMINATED","sponsor":"Sabyasachi Sen","startDate":"2018-10-22","conditions":"Diabetes Mellitus, Type 2, Cardiovascular Diseases","enrollment":15},{"nctId":"NCT03608358","phase":"PHASE3","title":"Safety and Efficacy of Dapagliflozin in Asian T2DM Subjects With Inadequate Glycemic Control on Metformin/Saxagliptin","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2019-02-27","conditions":"Type 2 Diabetes Mellitus","enrollment":41},{"nctId":"NCT02917031","phase":"PHASE4","title":"Mechanistic Evaluation of Glucose-lowering Strategies in Patients With Heart Failure","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2017-01-10","conditions":"Type 2 Diabetes Mellitus, Heart Failure","enrollment":348},{"nctId":"NCT02547935","phase":"PHASE2, PHASE3","title":"A Study to Evaluate the Effect of Dapagliflozin With and Without Saxagliptin on Albuminuria, and to Investigate the Effect of Dapagliflozin and Saxagliptin on HbA1c in Patients With Type 2 Diabetes and CKD","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2015-09-21","conditions":"Type 2 Diabetes Mellitus, CKD and Albuminuria","enrollment":459},{"nctId":"NCT02024477","phase":"PHASE4","title":"Effect of Saxagliptin on EPCs as a Cellular Biomarker for Evaluating Endothelial Dysfunction in Early T2DM Patients","status":"COMPLETED","sponsor":"George Washington University","startDate":"2013-11","conditions":"Type 2 Diabetes","enrollment":42},{"nctId":"NCT02284893","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-09-09","conditions":"Type 2 Diabetes","enrollment":461},{"nctId":"NCT01606007","phase":"PHASE3","title":"Safety and Efficacy of Combination Saxagliptin & Dapagliflozin Added to Metformin to Treat Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2012-07","conditions":"Type 2 Diabetes","enrollment":1282},{"nctId":"NCT01204775","phase":"PHASE3","title":"Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Saxagliptin as Monotherapy in Pediatric Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2011-06","conditions":"Type 2 Diabetes","enrollment":26},{"nctId":"NCT01434186","phase":"PHASE3","title":"A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Saxagliptin (BMS-477118) in Combination With Metformin IR or Metformin XR in Pediatric Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2012-05","conditions":"Diabetes Mellitus, Type 2","enrollment":32},{"nctId":"NCT01646320","phase":"PHASE3","title":"Safety and Efficacy of Dapagliflozin in Triple Therapy to Treat Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2012-09","conditions":"Type 2 Diabetes","enrollment":320},{"nctId":"NCT01619059","phase":"PHASE3","title":"Safety and Efficacy of Saxagliptin in Triple Therapy to Treat Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2012-06","conditions":"Type 2 Diabetes","enrollment":315},{"nctId":"NCT00918138","phase":"PHASE3","title":"Study To Evaluate 24 Hour Blood Sugar Control (24-hour Mean Weighted Glucose) In Subjects That Are Taking Saxagliptin 5 mg Added Onto Metformin XR 1500 XR mg Compared To Subjects Taking Metformin XR 1500 mg Up-titrated To Metformin XR 2000 mg","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2009-08","conditions":"Type 2 Diabetes","enrollment":219},{"nctId":"NCT00121641","phase":"PHASE3","title":"Saxagliptin Treatment in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2005-07","conditions":"Diabetes Mellitus, Type 2","enrollment":1035},{"nctId":"NCT00614939","phase":"PHASE3","title":"Treatment Effect of Saxagliptin Compared With Placebo in Patients With Type 2 Diabetes and Renal Impairment","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2008-01","conditions":"Type 2 Diabetes","enrollment":572}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":6,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo matching Saxagliptin","genericName":"Placebo matching Saxagliptin","companyName":"AstraZeneca","companyId":"astrazeneca","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This is a placebo control formulation matching Saxagliptin, a DPP-4 inhibitor that increases incretin hormone levels to stimulate insulin secretion in response to glucose. Used for Placebo control for type 2 diabetes mellitus trials.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}